Together, these data position MMP-9 not as a bystander marker but as an executable node that integrates inflammatory activation with structural barrier impairment; then also rationalize therapeutic strategies that pair endothelial-protective agents with precise MMP-9 inhibition to restore vascular integrity in inflammatory and ischemic disease states. Here, MMP9 is linked to ischemic disease.